Use your browser's back button to choose another title or click here for a New Search.



How to Get the Article

 Email CTN Library (free)

PubMed Central (free)

Journal subscriber access

 

 Comments?

 

Bookmark and Share

 

 

Opioid Withdrawal, Craving, and Use During and After Outpatient Buprenorphine Stabilization and Taper: A Discrete Survival and Growth Mixture Model.

Addictive Behaviors 2015;41:20-28. [doi: 10.1016/j.addbeh.2014.09.021]

Thomas F. Northrup, PhD (University of Texas-Houston Medical School, TX Node), Angela L. Stotts, PhD (University of Texas-Houston Medical School, TX Node), Charles Green, PhD (University of Texas-Houston Medical School, TX Node), Jennifer Sharpe Potter, PhD, MPH (McLean Hospital, NEC Node), Elise N. Marino (University of Texas, San Antonio, TX Node), N. Robrina Walker, PhD (University of Texas Southwestern Medical Center, TX Node), Roger D. Weiss, MD (McLean Hospital, NEC Node), Madhukar H. Trivedi, MD (University of Texas Southwestern Medical Center, TX Node).

Most patients relapse to opioids within one month of opioid agonist detoxification, making the antecedents and parallel processes of first use critical for investigation. Craving and withdrawal are often studied in relationship to opioid outcomes, and a novel analytic strategy applied to these two phenomena may indicate targeted intervention strategies. Specifically, this secondary data analysis of the National Drug Abuse Treatment Clinical Trials Network Prescription Opioid Addiction Treatment Study (POATS, CTN-0030) used a discrete-time mixture analysis with time-to-first opioid use (survival) simultaneously predicted by craving and withdrawal growth trajectories. This analysis characterized heterogeneity among prescription opioid-dependent individuals (N=653) into latent classes (i.e., latent class analysis [LCA]) during and after buprenorphine/naloxone stabilization and taper. A 4-latent class solution was selected for overall model fit and clinical parsimony. In order of shortest to longest time-to-first use, the 4 classes were characterized as 1) high craving and withdrawal; 2) intermediate craving and withdrawal; 3) high initial craving with low craving and withdrawal trajectories; and 4) a low initial craving with low craving and withdrawal trajectories. Odds ratio calculations showed statistically significant differences in time-to-first use across classes.

Conclusions: Generally, participants with lower baseline levels and greater decreases in craving and withdrawal during stabilization combined with slower craving and withdrawal rebound during buprenorphine taper remained opioid-free longer. This exploratory work expanded on the importance of monitoring craving and withdrawal during buprenorphine induction, stabilization, and taper. Future research may allow individually tailored and timely interventions to be developed to extend time-to-first opioid use. (Article (Peer-Reviewed), PDF, English, 2015)

Keywords: Buprenorphine/Naloxone | Craving | CTN platform/ancillary study | Opioid dependence | Pharmacological therapy | Prescription-type opiates | Suboxone | Urinalysis | Addictive Behaviors (journal)

Document No: 1102, PMID: 25282598, PMCID: PMC4252696.

Submitted by CTN Dissemination Librarians, 10/8/2014.

AUTHORS SEARCH LINK
Green, Charles search
Marino, Elise N. search mail
Northrup, Thomas F. search mail
Potter, Jennifer Sharpe search
Stotts, Angela L. search mail
Trivedi, Madhukar H. search mail
Walker, N. Robrina search mail
Weiss, Roger D. search mail
PROTOCOLS
NIDA-CTN-0030 search www
PARTICIPATING NODES    
New England Consortium (Lead) search www
Pacific Region (Lead) search www
Appalachian Tri-State search www
Greater New York search www
Ohio Valley search www
Pacific Northwest search www
Southern Consortium search www
Texas search www
Western States search www

Supported by a grant from the National Institute on Drug Abuse to the University of Washington Alcohol and Drug Abuse Institute.
The materials on this site have neither been created nor reviewed by NIDA.
Updated 2/2016 -- http://ctndisseminationlibrary.org/display/1102.htm
info@ctndisseminationlibrary.org